Wave Life Sciences Ltd. (NASDAQ:WVE) Insider Chris Francis Sells 36,000 Shares

Wave Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 36,000 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $576,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Chris Francis also recently made the following trade(s):

• On Wednesday, October 16th, Chris Francis sold 208,836 shares of Wave Life Sciences stock. The shares were sold at an average price of $13.67, for a total value of $2,854,788.12.

Wave Life Sciences Stock Performance

Shares of NASDAQ WVE opened at $15.69 on Thursday. The company’s fifty day moving average is $10.40 and its two-hundred day moving average is $7.41. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.19). Wave Life Sciences had a negative return on equity of 694.73% and a negative net margin of 66.50%. The company had revenue of ($7.68) million for the quarter, compared to analysts’ expectations of $15.45 million. On average, equities analysts predict that Wave Life Sciences Ltd. will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Wave Life Sciences

Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Wave Life Sciences by 50.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock valued at $45,000 after purchasing an additional 2,451 shares in the last quarter. Profund Advisors LLC acquired a new stake in shares of Wave Life Sciences during the 2nd quarter worth about $53,000. Principal Financial Group Inc. acquired a new position in shares of Wave Life Sciences in the second quarter valued at approximately $74,000. Finally, Mackenzie Financial Corp lifted its stake in shares of Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after buying an additional 1,905 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com cut shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday. Wells Fargo & Company increased their price objective on Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. upped their price target on Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.89.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.